|
Kidney Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In the present study, we examined effects of renin-angiotensin system (RAS) on cardiac hypertrophy and renal disorders using Tsukuba hypertensive mice.
|
9607405 |
1998 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The renin-angiotensin-aldosterone system (RAAS) plays a key role in the pathophysiology of arterial hypertension as well as in more complex mechanisms of cardiovascular and renal diseases.
|
28598381 |
2017 |
|
Kidney Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Thus, our data, in this large and ethnically homogeneous group of patients, do not support the hypothesis that these genetic variants of the renin-angiotensin system are strongly associated with either nephropathy or hypertension in patients with insulin-dependent or non-insulin-dependent diabetes mellitus.
|
9049480 |
1997 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
CTD_human |
Immunosuppressive treatment protects against angiotensin II-induced renal damage.
|
12414515 |
2002 |
|
Kidney Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
These include: (1) the intra-renal renin-angiotensin system (RAS), one based on molecular variations in angiotensinogen; (2) the Na, K, 2Cl cotransporter (NKCC2) and its regulators in the thick ascending limb, which are associated with a variety of phenotypes consistent with a more active cotransporter in blacks; and (3) the genes for MYH9 and APOL 1, which have been associated with kidney disease in blacks.
|
23397215 |
2013 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The renin-angiotensin system (RAS) plays an important role in the initiation and progression of cardiovascular and renal diseases.
|
28694144 |
2017 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Genotypes of the renin-angiotensin system have been implicated in essential hypertension and in progression of native kidney diseases, but gene effects on progression in chronic renal allograft dysfunction are unclear.
|
12548125 |
2003 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
CTD_human |
Prediction of renal impairment in elderly patients with congestive heart failure treated with captopril.
|
8723173 |
1996 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The levels of the full-length form of the (pro)renin receptor (PRR), a component of the renin-angiotensin system (RAS), may be reduced in the membranes of kidneys in renal diseases.
|
30843967 |
2019 |
|
Kidney Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We speculate that presymptomatic patients with normal renal function who have genetic or familial FSGS may benefit from early blockade of the renin-angiotensin axis and that this may also prevent progressive renal disease.
|
17530296 |
2007 |
|
Kidney Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Angiotensin II, the most vasoactive component of the renin-angiotensin-aldosterone (RAAS) pathway, can contribute to renal disease by causing an increase in arterial blood pressure leading to glomerular injury and fibrosis.
|
18206321 |
2008 |
|
Kidney Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
A novel REN gene mutation resulted in an alteration in the amino acid sequence of the renin signal sequence and caused childhood anemia, polyuria, and kidney disease.
|
21084044 |
2010 |
|
Kidney Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Genetics of the renin-angiotensin system and renal disease: a progress report.
|
9146976 |
1997 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Hypertension is an inflammatory condition controlled by the renin angiotensin system and is linked to kidney disease, diabetes mellitus, and recently to dysfunction of the gut.
|
27903643 |
2017 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Early Renin-angiotensin System Blockade Improved Short-term and Longterm Renal Outcomes in Systemic Lupus Erythematosus Patients with Antiphospholipid-associated Nephropathy.
|
29449503 |
2018 |
|
Kidney Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Significance of genetic polymorphisms of the renin-angiotensin-aldosterone system in cardiovascular and renal disease.
|
19290794 |
2009 |
|
Kidney Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The present study examined the role of (pro)renin receptor (PRR) in pathogenesis of albumin overload (AO)-induced nephropathy and activation of the intrarenal renin-angiotensin system (RAS) in rats.
|
29846109 |
2018 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Our data suggest the application of a renin inhibitor for preventing kidney disease progression in CKD patients.
|
24154707 |
2014 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Klotho suppresses the renin-angiotensin system in adriamycin nephropathy.
|
27798196 |
2017 |
|
Kidney Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Finally, half of the patients in all three age groups with heart failure and kidney disease received treatment with renin-angiotensin-system inhibitors; about two out of five patients received beta-blockers, while prescription rates of aldosterone inhibitors were low.
|
30187290 |
2018 |
|
Kidney Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Genetic variants of the renin-angiotensin system (RAS) have been implicated in the progression of native kidney diseases.
|
11923700 |
2002 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Renin-angiotensin genes in renal development and the occurrence and progression of renal diseases.
|
10192247 |
1999 |
|
Kidney Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We examined an association of the three renin-angiotensin system (RAS) gene polymorphisms with renal disease and progression to ESRD in dialyzed patients.
|
16384824 |
2006 |
|
Kidney Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The involvement of renin-angiotensin system (RAS) gene polymorphisms in the pathogenesis of nephropathy has been described predominantly in Caucasian populations.
|
11200871 |
2001 |
|
Kidney Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The importance of the RAS in the development and pathogenesis of cardiovascular, hypertensive and kidney diseases has now been firmly established in clinical trials and practice using renin inhibitors, angiotensin-converting enzyme (ACE) inhibitors, type 1 (AT<sub>1</sub>) angiotensin II (ANG II) receptor blockers (ARBs), or aldosterone receptor antagonists as major therapeutic drugs.
|
28619367 |
2017 |